ELTX•Elicio Therapeutics said its Phase 2 AMPLIFY-7P trial of camupepimut missed its primary disease-free survival endpoint. The company plans to discuss a potential Phase 3 trial with the FDA.
The AMPLIFY-7P trial of camupepimut in pancreatic cancer missed its primary disease-free survival endpoint. Prespecified subgroup analyses favored treatment, but an imbalance in baseline recurrence risk complicated interpretation of the overall results. Camupepimut was generally well tolerated, with no new safety signals or adverse events leading to treatment withdrawal. Elicio plans FDA discussions on a potential Phase 3 trial, including patient stratification, treatment duration and combination strategies.
